227Th-EDTMP: a potential therapeutic agent for bone metastasis.

The biodistribution of 227Th-EDTMP and retention of its daughter nuclide 223Ra were examined. 227Th-EDTMP was found to show high uptake and long-term retention in bone. The clearance of 227Th-EDTMP from blood and soft tissues was rapid and the femur-to-tissue uptake ratios reached more than 100 within 30 min for all tissues except the kidney. Seven and 14 days after injection of 227Th-EDTMP, the retention index of 223Ra in bone showed high values, and the differences between these time points were not significant. Therefore, 227Th-EDTMP is a potential radiotherapeutic agent for bone metastasis.
AuthorsKohshin Washiyama, Ryohei Amano, Jun Sasaki, Seigo Kinuya, Norihisa Tonami, Yoshinobu Shiokawa, Toshiaki Mitsugashira
JournalNuclear medicine and biology (Nucl Med Biol) Vol. 31 Issue 7 Pg. 901-8 (Oct 2004) ISSN: 0969-8051 [Print] England
PMID15464392 (Publication Type: Evaluation Studies, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 227Th-ethylenediamine-tetramethylenephosphonic acid
  • Organometallic Compounds
  • Organophosphonates
  • Radiopharmaceuticals
  • Animals
  • Bone Neoplasms (metabolism, radiotherapy)
  • Feasibility Studies
  • Femur (metabolism)
  • Male
  • Metabolic Clearance Rate
  • Mice
  • Mice, Inbred ICR
  • Organ Specificity
  • Organometallic Compounds (chemistry, pharmacokinetics, therapeutic use)
  • Organophosphonates (chemistry, pharmacokinetics, therapeutic use)
  • Radiopharmaceuticals (chemical synthesis, pharmacokinetics, therapeutic use)
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: